Ischemic Stroke
Conditions
Brief summary
The purpose of this study is to determine the safety and feasibility of remote limb ischemic conditioning(RIC) in acute ischemic stroke patients who received r-tPA thrombolytic therapy.
Interventions
DEVICERemote ischemic conditioning
In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. Doctormate, IPC-906
Sponsors
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, age≥18; * Acute ischemic stroke; * modified Rankin Scale (mRS) score of 2-5; * mRS score less than 1 before onset of stroke symptom; * Onset of stroke symptoms within 4.5h before initiation of intravenous rt-PA thrombolytic therapy; * Good compliance for Remote Ischemic Conditioning(RIC) therapy; * Informed consent obtained.
Exclusion criteria
* Stroke or serious head trauma within the previous 3 months * Major surgery or severe trauma with in the preceding 3 months * Intracranial hemorrhage * Systolic pressure greater than 185 mm Hg or diastolic pressure greater than 110 mm Hg, or aggressive treatment intravenous medication) necessary to reduce blood pressure to these limits * Symptoms rapidly improving * Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal * Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days * Arterial puncture at a noncompressible site within the previous 7 days * Seizure at the onset of stroke * Platelet count of less than 100,000 per cubic millimeter * Received heparin within the 48 hours preceding the onset of stroke and had an elevated partial-thromboplastin time * Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds * CT showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere) * Use or plan to use intervention for diagnosis or treating * Intracranial neoplasm, cerebral aneurysm or arteriovenous malformation * severe hepatic or renal dysfunction * Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs. * Life expectancy\<1 years * Pregnant or breast-feeding women * Unwilling to be followed up or poor compliance for treatment * Patients being enrolled or having been enrolled
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of RIC after acute ischemic stroke | 7 days | The proportion of enrolled subjects that completed all the designed RIC procedures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with intracranial hemorrhage in two groups | 7(±24h)days | — |
| Scores assessed by National Institutes of Health Stroke Scale(NIHSS) | 7(±24h)days | — |
| The functional outcome at 90 days assessed by modified Rankin scale (mRS). | 90( ±7days) days | — |
| functional outcome assessed by Barthel Index(BI) | 90( ±7days)days | — |
| cerebral infarct volume. | 3-7 days after stroke onset | The infarct volume of cerebral infarct is evaluated by cranial noncontrast MRI |
| Cardiovascular parameters during 7 days of RIC treatment. | 7 days | the blood pressure were measured immediately before RIC and also be measured 5 minutes after RIC. |
| Objective signs of tissue or neurovascular injury | within 7(±24h) days | objective signs of tissue or neurovascular injury felt to be due to cuff inflation. Inspection included palpation of distal radial pulses, visual inspection (for local edema, redness, skin breakdown), and palpation for tenderness |
| Levels of plasma myoglobin | baseline and 7(±2)days | — |
| Levels of serum IL-6 | baseline and 7(±2)days | — |
| Levels of serum HS-CRP | baseline and 7(±2)days | — |
| Levels of serum HCY | baseline and 7(±2)days | — |
| Any adverse events | 90(±7)days | — |
| the heart rate during 7 days of RIC treatment. | 7 days | the heart rate were measured immediately before RIC and also be measured 5 minutes after RIC. |
Countries
China
Outcome results
None listed